follow @HspNews
RSS Feeds
Find Us on Facebook

Infectious Diseases

FDA to Limit Cephalosporin Use in Food Animals

By: KERRI WACHTER, Hospitalist News Digital Network

The Food and Drug Administration will prohibit certain uses of cephalosporins in specific food animals in an attempt to preserve the antibiotics’ effectiveness for treating human infections.

In an order issued Jan. 4, the FDA said that by April it will prohibit unapproved uses of cephalosporins in cattle, swine, chickens, and turkeys.

The order prohibits the use of cephalosporin drugs for disease prevention in food animals. Furthermore, only cephalosporin drugs that have been approved for use in cattle, swine, chickens, or turkeys are permitted for use in those species. The order also prohibits giving food animals cephalosporins at unapproved dose levels, frequencies, durations, or routes of administration. Cephalosporins that are intended for use in humans or companion animals are prohibited for use in food animals.

The decision comes more than 3 years after the agency revoked a July 2008 decision to prohibit without exception all "extralabel" uses of cephalosporins in food-producing animals. The agency revoked the original order after receiving comments from approximately 170 organizations or individuals. According to the FDA, scientific review of those comments was factored into the new order, which was greeted with support by physicians and groups concerned about the emergence of antibiotic resistance.

"Physicians must be able to rely on proven, safe, and effective medications to provide optimal care to their patients," Dr. Peter W. Carmel, president of the American Medical Association, said in a statement. "By taking this step, physicians can continue to have this class of antibiotics available to successfully fight bacterial meningitis and other serious infections."

"It’s wonderful that FDA made this move," Dr. James R. Johnson said in an interview.

Cephalosporins are "a hugely important group of antibiotics. These are workhorse, frontline, mainstream antibiotics," said Dr. Johnson, a member of the Infectious Disease Society of America’s Antimicrobial Resistance Work Group.

Cephalosporins are active against gram-positive and gram-negative bacteria, and "the biggest concern right now is resistance against gram-negatives. That’s where agricultural use has been thought to be contributing in an important way to the resistance problem – particularly salmonella and [Escherichia coli]."

Unfortunately, there are few antibiotics in development against gram-negative bacteria. "The ones that are under development are on a timeline that means they are not going to be available to us for years to come," he said.

"So we’re sort of in the position of holding on by our fingernails, dealing with these bad infections with the drugs that we currently have for the next however many years until new drugs become available," said Dr. Johnson, who is also a professor of medicine at the University of Minnesota, Minneapolis.

Dr. Johnson reported that he received grant support from several pharmaceutical companies.

01/09/12  

Bookmark and Share


Submitting your vote...
Not rated yet. Be the first who rates this item!
Click the rating bar to rate this item.

I would like to receive Hospitalist News E-Newsletter each week.


Specialty Focus


  Cardiovascular Disease

  Diabetes, Endocrinology & Metabolism

  Gastroenterology

  Hematology/Thrombosis

  Imaging

  Infectious Diseases

  Nephrology

  Neurology & Pain

  Palliative/Hospice

  Pediatrics

  Perioperative Medicine

  Practice Trends

  Psychiatry

  Pulmonary Disease

  Trauma


calendar
May 11 - 21
Departs Civitavecchia,
Rheumatology and Orthopaedics
May 11 - 21
Departs Civitavecchia,
Rheumatology and Orthopaedics
May 12 - 21
Departs Oslo,
Pain Management/Neurology/Compliance
May 15 - 18
Paris,
European Association of Percutaneous Cardiovascular Interventions (EAPCI): EuroPCR
May 16 - 19
Melbourne,
World Federation for NeuroRehabilitation (WFNR): 7th World Congress of Neurorehabilitation (WCNR2012)
May 16 - 19
Denver, CO
Pediatric Orthopaedic Society of North America (POSNA): Annual Meeting
May 16 - 19
Honolulu, HI
American Pain Society (APS): Annual Scientific Meeting
May 16 - 20
Marrakesh,
8th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
May 16 - 19
Istanbul,
European Society for Pediatric Dermatology (ESPD): 11th Congress
May 16 - 19
Istanbul,
European Society for Pediatric Dermatology (ESPD): 11th Congress
More Calendar »